Novavax (NVAX) ended the recent trading session at ... Meanwhile, the Dow experienced a rise of 1.65%, and the technology-dominated Nasdaq saw an increase of 2.45%. Coming into today, shares ...

$100,000 of NOVAVAX INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...

Three of VBK's underlying holdings with notable upside to their analyst target prices are Evolent Health Inc (Symbol: EVH), MediaAlpha Inc (Symbol: MAX), and Novavax, Inc. (Symbol: NVAX).

In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) crossed above their 200 day moving average of $10.66, changing hands as high as $11.55 per share. Novavax, Inc. shares are currently ...

Shares of Novavax Inc. NVAX slid 3.46% to $9.22 Friday, on what proved to be an all-around rough trading session for the ...

Investors in Novavax, Inc. (Symbol: NVAX) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX ...

CureVac is developing this investigational mRNA-based vaccine in collaboration with GSK. Novavax NVAX is also developing a bird flu vaccine in preclinical studies. NVAX claimed that this vaccine ...

Novavax NVAX shares soared 10.9% in the last trading session to close at $10.82. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have been given a consensus recommendation of “Hold” by the six ratings firms that are covering the firm, Marketbeat reports.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Any recent changes to analyst estimates for Novavax should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...